Beam Therapeutics Inc.: Form 10-Q for the period ended Jun 30, 2021
Filed with the SEC on Aug 10, 2021 and accepted by EDGAR at Aug 10, 2021, 07:46 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2021-06-30. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 3 months2021-04-01 to 2021-06-30 | $6.0k | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Revenue | 6 months2021-01-01 to 2021-06-30 | $12.0k | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Research and development | 3 months2021-04-01 to 2021-06-30 | $45.6m | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 6 months2021-01-01 to 2021-06-30 | $235.7m | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 3 months2021-04-01 to 2021-06-30 | −$59.0m | us-gaap:OperatingIncomeLoss |
| Operating income | 6 months2021-01-01 to 2021-06-30 | −$259.3m | us-gaap:OperatingIncomeLoss |
| Net income | 3 months2021-04-01 to 2021-06-30 | −$76.3m | us-gaap:NetIncomeLoss |
| Net income | 6 months2021-01-01 to 2021-06-30 | −$277.8m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months2021-04-01 to 2021-06-30 | −$1.23 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 6 months2021-01-01 to 2021-06-30 | −$4.54 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months2021-04-01 to 2021-06-30 | −$1.23 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 6 months2021-01-01 to 2021-06-30 | −$4.54 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months2021-04-01 to 2021-06-30 | 62,210,239 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 6 months2021-01-01 to 2021-06-30 | 61,215,705 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 6 months2021-01-01 to 2021-06-30 | −$71.1m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 6 months2021-01-01 to 2021-06-30 | $27.7m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | At period end2021-06-30 | $212.0m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2021-06-30 | $678.0m | us-gaap:AssetsCurrent |
| Total assets | At period end2021-06-30 | $893.1m | us-gaap:Assets |
| Current liabilities | At period end2021-06-30 | $128.7m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2021-06-30 | $344.5m | us-gaap:Liabilities |
| Shareholders' equity | At period end2021-06-30 | $548.6m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0000950170-21-001110. Last ingested by Listed: Nov 14, 2026, 12:58 ET. Listed shows no prices and gives no investment advice.